Company profile: Mipharm
1.1 - Company Overview
Company description
- Provider of pharmaceutical manufacturing across oral solids, oral liquids, nasal sprays, semi-solids, and suppositories; customized and secure packaging; research and development for new formulations and optimization of existing ones; clinical trial logistics; and formulation development and production of experimental drugs for clinical trials.
Products and services
- Ricerca e Sviluppo (Research and Development): Custom-engineered program that develops new pharmaceutical formulations and optimizes existing ones, architecting compositions tailored to targeted applications within the pharmaceutical industry
- Produzione (Production): Multi-dosage-format operation that produces pharmaceutical products across oral solids, oral liquids, nasal sprays, semi-solids, and suppositories, ensuring consistent fabrication across these stated dosage formats
- Sviluppo Formulativo e Produzione di Farmaci per Uso Sperimentale (Formulation Development and Production of Experimental Drugs): Experimental-use process that engineers formulations and fabricates drugs specifically for clinical trials, focusing on development and production activities dedicated to trial-bound pharmaceutical products
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Mipharm
Suono Bio
HQ: United States
Website
- Description: Provider of ultrasound-mediated drug delivery platforms enabling ultra-rapid delivery of small molecules, biologics, and nucleic acids to the gastrointestinal tract and directly into cells without encapsulation; offerings include Ultrasonic Enhanced Delivery and SuonoCalm for treating inflammatory conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Suono Bio company profile →
Bioject
HQ: United States
Website
- Description: Provider of needle-free injection therapies to improve administration of liquid medications, including pharmaceuticals, vaccines, and biologics, using technology that forces medication at high speed through a tiny orifice held against the skin, with over 25 years of experience.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bioject company profile →
Lipocine
HQ: United States
Website
- Description: Provider of specialty pharmaceutical products, including TLANDO, an FDA-approved oral testosterone replacement therapy; LPCN 1111, an oral testosterone prodrug for hypogonadal men; LPCN 1144 and 1148, oral prodrugs of bioidentical testosterone for NASH and cirrhosis symptoms; LPCN 1107, an oral candidate to prevent recurrent preterm birth (FDA orphan drug); and LPCN 1154, an oral neurosteroid for postpartum depression.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lipocine company profile →
Travanti Pharma
HQ: United States
Website
- Description: Provider of innovative drug delivery platforms that improve the safety, compliance, effectiveness, and ease of administration of medications delivered into the body; designs, develops, and markets these platforms to enhance medication delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Travanti Pharma company profile →
Lyra Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage therapeutics for ear, nose, and throat diseases, including LYR-210 and LYR-220, bioabsorbable nasal mesh implants that deliver up to six months of continuous mometasone furoate for chronic rhinosinusitis, and the XTreo platform, a proprietary technology for direct, consistent, sustained drug delivery to affected tissues with a single administration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lyra Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Mipharm
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Mipharm
2.2 - Growth funds investing in similar companies to Mipharm
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Mipharm
4.2 - Public trading comparable groups for Mipharm
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →